在急性心力衰竭 (DIUR-AHF) 中不同循环利尿剂的剂量和使用:多中心前性观察性开放标签研究
Alberto Palazzuoli1, Filippo Pirrotta1, Andrea Stefanini2
1Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department le Scotte Hospital University of Siena Italy.
European journal of internal medicine
|June 3, 2025
概括
在急性心力衰竭 (AHF) 中,循环性尿剂的持续静脉输注 (CiV) 改善了NT-proBNP的减少和体重减轻,但与较差的结果有关. 高剂量 (HD) 罗西米德也会增加AHF患者的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 循环利尿剂 (LD) 对于急性心力衰竭 (AHF) 治疗至关重要.
- 在AHF中,最佳的LD给药方式仍然令人担忧.
- 这项研究调查了AHF的不同LD方案和剂量.
研究的目的:
- 为了比较持续静脉注射 (CiV) 与每天两次注射黄胺的静脉注射 (BiV) 在AHF患者中的效果.
- 为了评估高剂量 (HD) 富洛塞米德给药对AHF结局的影响.
- 评估主要终点,包括在6个月内重新住院或心血管死亡.
主要方法:
- 多中心前性观察性开放标签研究,涉及402名AHF患者.
- 患者接受了CiV或BiVfurosemide的治疗,持续72至120小时.
- 高剂量 (HD) 定义为>120 mg/天;符合条件的NT-proBNP>500 pg/ml和拥堵的迹象.
主要成果:
- 与BiV相比,CiV显示了较高的NT-proBNP下降 (63%vs45%) 和体重减轻 (-4.3vs-3.2公斤).
- BiV导致住院时间更短 (11.5 vs 12.7 天) 和不良事件更少 (29% vs 45%).
- 发病管理与长时间住院和较差的治疗结果有关 (55%对18%).
结论:
- 在AHF中使用的CiV furosemide可以改善尿酸的减少和减肥,但与较差的临床结果有关.
- 在AHF中高剂量罗塞米德增加了不良事件和再住院的风险.
- 胆固醇静脉注射 (BiV) 可能为AHF的LD注射提供更安全的替代方案.
相关概念视频
01:22Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:26Heart Failure Drugs: Inotropic Agents
747
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
747
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:22Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
01:11Renal Failure: Dose Adjustments
167
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
167